See the DrugPatentWatch profile for keytruda

FDA Approval Date for Keytruda: A Breakthrough in Cancer Treatment

The FDA approval date for Keytruda, a groundbreaking immunotherapy drug, marks a significant milestone in the fight against cancer. Developed by Merck & Co., Inc., Keytruda (pembrolizumab) has revolutionized the treatment landscape for various types of cancer, offering hope to patients and their families.

What is Keytruda?

Keytruda is a programmed death receptor-1 (PD-1) inhibitor, a type of immunotherapy that works by enhancing the body's natural defense against cancer cells. By blocking the PD-1 receptor on immune cells, Keytruda allows the immune system to recognize and attack cancer cells more effectively.

FDA Approval Date: A Timeline of Milestones

Keytruda's FDA approval date is a testament to the tireless efforts of researchers, scientists, and clinicians who have worked tirelessly to develop this life-changing treatment. Here's a brief timeline of Keytruda's FDA approval milestones:

* September 4, 2014: Keytruda receives FDA approval for the treatment of patients with unresectable or metastatic melanoma, a type of skin cancer.
* October 2015: Keytruda receives FDA approval for the treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).
* March 2017: Keytruda receives FDA approval for the treatment of patients with classical Hodgkin lymphoma (cHL) that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin.
* May 2017: Keytruda receives FDA approval for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy.
* June 2017: Keytruda receives FDA approval for the treatment of patients with locally advanced or metastatic urothelial carcinoma (mUC) that has disease progression during or after platinum-containing chemotherapy.
* October 2018: Keytruda receives FDA approval for the treatment of patients with locally advanced or metastatic urothelial carcinoma (mUC) that has disease progression during or after platinum-containing chemotherapy and has received prior treatment with a programmed death ligand 1 (PD-L1) inhibitor.
* March 2019: Keytruda receives FDA approval for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a PD-L1 tumor proportion score (TPS) ≥ 50%.
* June 2019: Keytruda receives FDA approval for the treatment of patients with locally advanced or metastatic NSCLC with a PD-L1 TPS ≥ 1%.
* October 2020: Keytruda receives FDA approval for the treatment of patients with locally advanced or metastatic NSCLC with a PD-L1 TPS ≥ 1% and a tumor mutation burden (TMB) ≥ 10 mutations per megabase.

Keytruda's Impact on Cancer Treatment

Keytruda's FDA approval date marks a significant milestone in the fight against cancer. This groundbreaking immunotherapy has revolutionized the treatment landscape for various types of cancer, offering hope to patients and their families. Keytruda's ability to enhance the body's natural defense against cancer cells has led to improved response rates, prolonged progression-free survival, and enhanced overall survival.

The Future of Cancer Treatment: Keytruda and Beyond

As researchers continue to explore the potential of immunotherapy, Keytruda's FDA approval date serves as a reminder of the incredible progress that has been made in the fight against cancer. With ongoing clinical trials and research, the future of cancer treatment looks brighter than ever, offering new hope to patients and their families.

Conclusion

Keytruda's FDA approval date is a testament to the tireless efforts of researchers, scientists, and clinicians who have worked tirelessly to develop this life-changing treatment. As we look to the future of cancer treatment, Keytruda's impact will continue to be felt, offering hope and new possibilities for patients and their families.

FAQs

1. What is Keytruda?
Keytruda is a programmed death receptor-1 (PD-1) inhibitor, a type of immunotherapy that works by enhancing the body's natural defense against cancer cells.
2. What is the FDA approval date for Keytruda?
Keytruda's FDA approval date is September 4, 2014, for the treatment of patients with unresectable or metastatic melanoma.
3. What types of cancer is Keytruda approved for?
Keytruda is approved for the treatment of various types of cancer, including melanoma, head and neck squamous cell carcinoma, classical Hodgkin lymphoma, urothelial carcinoma, and non-small cell lung cancer.
4. How does Keytruda work?
Keytruda works by blocking the PD-1 receptor on immune cells, allowing the immune system to recognize and attack cancer cells more effectively.
5. What is the future of cancer treatment with Keytruda?
As researchers continue to explore the potential of immunotherapy, Keytruda's FDA approval date serves as a reminder of the incredible progress that has been made in the fight against cancer. With ongoing clinical trials and research, the future of cancer treatment looks brighter than ever, offering new hope to patients and their families.

Cited Sources:

1. DrugPatentWatch.com. (n.d.). Pembrolizumab (Keytruda) FDA Approval History. Retrieved from <https://www.drugpatentwatch.com/fda-approval-history/pembrolizumab-keytruda>
2. Merck & Co., Inc. (n.d.). Keytruda (pembrolizumab). Retrieved from <https://www.merck.com/product/usa/picirculars/k/keytruda/keytrudapi.pdf>
3. FDA. (n.d.). Pembrolizumab (Keytruda). Retrieved from <https://www.fda.gov/drugs/drug-approvals-and-databases/pembrolizumab-keytruda>